vs
Lantheus Holdings, Inc.（LNTH）とSCANSOURCE, INC.（SCSC）の財務データ比較。上の社名をクリックして会社を切り替えられます
SCANSOURCE, INC.の直近四半期売上が大きい（$766.5M vs $406.8M、Lantheus Holdings, Inc.の約1.9倍）。Lantheus Holdings, Inc.の純利益率が高く（13.3% vs 2.2%、差は11.1%）。Lantheus Holdings, Inc.の前年同期比売上増加率が高い（4.0% vs 2.5%）。Lantheus Holdings, Inc.の直近四半期フリーキャッシュフローが多い（$81.4M vs $28.9M）。過去8四半期でLantheus Holdings, Inc.の売上複合成長率が高い（4.9% vs 0.9%）
ランティウス・ホールディングスはグローバルな医療企業で、革新的な診断用造影剤や関連ソリューションの開発・製造・販売を事業の核としています。製品は腫瘍学、循環器学、泌尿器学などの分野に対応し、北米を中心に世界の主要市場で事業を展開しています。
ScanSource社は世界有数の専門技術流通企業で、POSシステム、バーコードスキャナー、サイバーセキュリティ製品、クラウドサービス、通信ソリューションなどを取り扱い、北米・中南米・欧州の付加価値販売業者、サービスプロバイダー、企業顧客向けに事業を展開し、小売、医療、産業、公共部門を主な対象分野としています。
LNTH vs SCSC — 直接比較
損益計算書 — Q4 FY2025 vs Q2 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $406.8M | $766.5M |
| 純利益 | $54.1M | $16.5M |
| 粗利率 | 59.2% | 13.4% |
| 営業利益率 | 19.0% | 2.3% |
| 純利益率 | 13.3% | 2.2% |
| 売上前年比 | 4.0% | 2.5% |
| 純利益前年比 | 558.8% | -3.3% |
| EPS（希薄化後） | $0.86 | $0.75 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $406.8M | $766.5M | ||
| Q3 25 | $384.0M | $739.6M | ||
| Q2 25 | $378.0M | $812.9M | ||
| Q1 25 | $372.8M | $704.8M | ||
| Q4 24 | $391.1M | $747.5M | ||
| Q3 24 | $378.7M | $775.6M | ||
| Q2 24 | $394.1M | $746.1M | ||
| Q1 24 | $370.0M | $752.6M |
| Q4 25 | $54.1M | $16.5M | ||
| Q3 25 | $27.8M | $19.9M | ||
| Q2 25 | $78.8M | $20.1M | ||
| Q1 25 | $72.9M | $17.4M | ||
| Q4 24 | $-11.8M | $17.1M | ||
| Q3 24 | $131.1M | $17.0M | ||
| Q2 24 | $62.1M | $16.1M | ||
| Q1 24 | $131.1M | $12.8M |
| Q4 25 | 59.2% | 13.4% | ||
| Q3 25 | 57.9% | 14.5% | ||
| Q2 25 | 63.8% | 12.9% | ||
| Q1 25 | 63.8% | 14.2% | ||
| Q4 24 | 63.5% | 13.6% | ||
| Q3 24 | 63.9% | 13.1% | ||
| Q2 24 | 64.9% | 13.0% | ||
| Q1 24 | 65.4% | 12.6% |
| Q4 25 | 19.0% | 2.3% | ||
| Q3 25 | 11.4% | 3.5% | ||
| Q2 25 | 23.3% | 3.3% | ||
| Q1 25 | 27.4% | 3.2% | ||
| Q4 24 | 29.1% | 2.5% | ||
| Q3 24 | 35.3% | 2.3% | ||
| Q2 24 | 26.1% | 2.9% | ||
| Q1 24 | 28.8% | 2.3% |
| Q4 25 | 13.3% | 2.2% | ||
| Q3 25 | 7.2% | 2.7% | ||
| Q2 25 | 20.8% | 2.5% | ||
| Q1 25 | 19.6% | 2.5% | ||
| Q4 24 | -3.0% | 2.3% | ||
| Q3 24 | 34.6% | 2.2% | ||
| Q2 24 | 15.8% | 2.2% | ||
| Q1 24 | 35.4% | 1.7% |
| Q4 25 | $0.86 | $0.75 | ||
| Q3 25 | $0.41 | $0.89 | ||
| Q2 25 | $1.12 | $0.87 | ||
| Q1 25 | $1.02 | $0.74 | ||
| Q4 24 | $-0.18 | $0.70 | ||
| Q3 24 | $1.79 | $0.69 | ||
| Q2 24 | $0.88 | $0.66 | ||
| Q1 24 | $1.87 | $0.50 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $359.1M | $83.5M |
| 総負債低いほど良い | $568.7M | — |
| 株主資本純資産 | $1.1B | $910.9M |
| 総資産 | $2.2B | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | 0.52× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $359.1M | $83.5M | ||
| Q3 25 | $382.0M | $124.9M | ||
| Q2 25 | $695.6M | $126.2M | ||
| Q1 25 | $938.5M | $146.3M | ||
| Q4 24 | $912.8M | $110.5M | ||
| Q3 24 | $866.4M | $145.0M | ||
| Q2 24 | $757.0M | $185.5M | ||
| Q1 24 | $718.3M | $159.1M |
| Q4 25 | $568.7M | — | ||
| Q3 25 | $567.9M | — | ||
| Q2 25 | $566.8M | — | ||
| Q1 25 | $566.1M | — | ||
| Q4 24 | $565.3M | — | ||
| Q3 24 | $613.0K | — | ||
| Q2 24 | $563.2M | — | ||
| Q1 24 | $562.5M | — |
| Q4 25 | $1.1B | $910.9M | ||
| Q3 25 | $1.1B | $914.0M | ||
| Q2 25 | $1.2B | $906.4M | ||
| Q1 25 | $1.2B | $901.7M | ||
| Q4 24 | $1.1B | $900.7M | ||
| Q3 24 | $1.2B | $920.9M | ||
| Q2 24 | $1.0B | $924.3M | ||
| Q1 24 | $945.5M | $944.1M |
| Q4 25 | $2.2B | $1.7B | ||
| Q3 25 | $2.3B | $1.7B | ||
| Q2 25 | $2.1B | $1.8B | ||
| Q1 25 | $2.1B | $1.7B | ||
| Q4 24 | $2.0B | $1.7B | ||
| Q3 24 | $2.0B | $1.8B | ||
| Q2 24 | $1.9B | $1.8B | ||
| Q1 24 | $1.8B | $1.8B |
| Q4 25 | 0.52× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.49× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.55× | — | ||
| Q1 24 | 0.59× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $90.2M | $30.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $81.4M | $28.9M |
| FCFマージンFCF / 売上 | 20.0% | 3.8% |
| 設備投資強度設備投資 / 売上 | 2.2% | 0.3% |
| キャッシュ転換率営業CF / 純利益 | 1.67× | 1.87× |
| 直近12ヶ月FCF直近4四半期 | $354.1M | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $90.2M | $30.8M | ||
| Q3 25 | $105.3M | $23.2M | ||
| Q2 25 | $87.1M | — | ||
| Q1 25 | $107.6M | $66.1M | ||
| Q4 24 | $157.7M | $-6.2M | ||
| Q3 24 | $175.1M | $44.8M | ||
| Q2 24 | $84.7M | — | ||
| Q1 24 | $127.2M | $160.2M |
| Q4 25 | $81.4M | $28.9M | ||
| Q3 25 | $94.7M | $20.8M | ||
| Q2 25 | $79.1M | — | ||
| Q1 25 | $98.8M | $64.6M | ||
| Q4 24 | $141.4M | $-8.2M | ||
| Q3 24 | $159.3M | $42.5M | ||
| Q2 24 | $73.5M | — | ||
| Q1 24 | $119.0M | $157.7M |
| Q4 25 | 20.0% | 3.8% | ||
| Q3 25 | 24.7% | 2.8% | ||
| Q2 25 | 20.9% | — | ||
| Q1 25 | 26.5% | 9.2% | ||
| Q4 24 | 36.1% | -1.1% | ||
| Q3 24 | 42.0% | 5.5% | ||
| Q2 24 | 18.7% | — | ||
| Q1 24 | 32.2% | 21.0% |
| Q4 25 | 2.2% | 0.3% | ||
| Q3 25 | 2.8% | 0.3% | ||
| Q2 25 | 2.1% | 0.3% | ||
| Q1 25 | 2.3% | 0.2% | ||
| Q4 24 | 4.2% | 0.3% | ||
| Q3 24 | 4.2% | 0.3% | ||
| Q2 24 | 2.8% | 0.2% | ||
| Q1 24 | 2.2% | 0.3% |
| Q4 25 | 1.67× | 1.87× | ||
| Q3 25 | 3.79× | 1.17× | ||
| Q2 25 | 1.11× | — | ||
| Q1 25 | 1.47× | 3.79× | ||
| Q4 24 | — | -0.36× | ||
| Q3 24 | 1.34× | 2.64× | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | 0.97× | 12.51× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
